Will HPCGG’s New Algorithm Spur Market Adoption of PGx-Based Warfarin Dosing? | GenomeWeb
BOSTON – The Harvard-Partners Center for Genetics and Genomics is partnering with the US Food and Drug Administration to develop a pharmacogenomics-based dosing algorithm for the widely prescribed anticoagulant warfarin.
News of the collaboration follows on the heels of a highly publicized clinical trial on pharmacogenomics-guided warfarin dosing that did not reach its primary endpoint, which could place personalized medicine in a bad light, according to some observers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.